Alzheimer's Disease, Pseudobulbar Affect (PBA)
Conditions
Brief summary
The primary objective of this study is to test the hypothesis that Nuedexta (20/10) administered orally will reduce Pseudobulbar Affect (PBA) frequency and severity (CNS-Lability Scale and PLACS), with satisfactory safety and high tolerability in patients with Alzheimer's Disease (AD). The primary objective will be evaluated using a study endpoint at 1, 13, 26 weeks after initiation of treatment. The secondary objective of this study is to evaluate the benefit of treatment with Nuedexta (20/10) on cognition and functionality as demonstrated in the Rey Auditory Verbal Learning Test (RAVLT), Trail making A and B, Wechsler Memory Scale (WMS) logical memory and delayed recall, Controlled Oral Word Association (COWA), Clinical Dementia Rating (CDR), Neuropsychiatric Inventory (NPI), Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCSADL) and the 11-item Alzheimer's Disease Assessment Scale-Cognitive subscore (ADAS-Cog11).
Interventions
DRUGNuedexta (20/10)
Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
Sponsors
Avanir Pharmaceuticals
St. Joseph's Hospital and Medical Center, Phoenix
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Male/female 55 to 90 years, inclusive. * Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable AD. * Modified Hachinski Ischemia Scale score of ≤4. * Folstein Mini Mental State Exam score 16-26 at Visit 1. * Geriatric Depression Scale score ≤6. For patient with history of depression, he/she have been on steady dose of anti-depressant for at least 3 months. * Clinical history and relevant symptoms of Pseudobulbar Affect. * Center for Neurologic Study-Lability Scale score at baseline ≥13. * Stable hematologic, hepatic, and renal function, with no clinically significant symptoms, and with clinical laboratory results (CBC, clinical chemistry, and urinalysis) up to 1-fold higher than upper limit of normal range. * Resting respiratory rate 12-20/minute. * MRI or CT scan within past 12 months; no findings inconsistent with diagnosis of AD. * ECG (within 4 weeks prior to entry)with no evidence of clinically significant abnormalities. * Concurrent treatment with an acetylcholinesterase inhibitor or memantine allowed; must be on stable dose at least 2 months before screening. Dosing must remain stable throughout the study. * Use of SSRI's allowed. Must have used for 3 months prior to study entry; dose must remain unchanged during course of study. * No current symptoms of depressive disorder. * Score of 19 or lower in the Beck Depression Inventory. * Agrees to use no prohibited medications during study.
Exclusion criteria
* Has current serious or unstable illnesses that, in investigator's opinion, could interfere with analysis of safety and efficacy data; has life expectancy \<2 years. * No reliable caregiver in frequent contact with patient (at least 10 hours/week. * Current or prior history of major psychiatric disturbance. * Have been in other clinical study within 30 days of entry. * Score of 20 or higher in Beck Depression Inventory. * Multiple episodes of head trauma, history within last year of serious infectious disease affecting the brain, head trauma resulting in protracted loss of consciousness, or myasthenia gravis. * Within the last 5 years, history of a primary or recurrent malignant disease. * Known sensitivity to quinidine or dextromethorphan. * History of human immunodeficiency virus, multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions. * History of chronic alcohol or drug abuse/dependence within the past 5 years. * Judged by investigator to be at serious risk for suicide. * Has a recent or current lab result indicating clinically significant lab abnormality. * At Visit 1 has ALT/SGPT values ≥2 times upper limit of normal (ULN); AST/SGOT values ≥3 times the ULN; total bilirubin values ≥2 times the ULN. * Resting diurnal oxygen saturation \<95%. * Received dextromethorphan and quinidine within previous 6 months. * Hypotension (systolic BP \<100 mm Hg); postural syncope; unexplained syncope. * Used medications that affect the CNS (except for AD) for less than 4 weeks. * On disallowed concomitant medications. * Experiencing acute exacerbation of underlying neurological disorder within previous 2 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduction of PBA frequency | 1, 13, and 26 weeks after initiation of treatment |
Secondary
| Measure | Time frame |
|---|---|
| reduction of PBA severity | 1, 13, and 26 weeks after initiation of treatment |
Countries
United States
Outcome results
None listed